Roche's Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness
Portfolio Pulse from
Roche's Vabysmo prefilled syringe has been approved by the European Medicines Agency for treating three retinal conditions, potentially benefiting over nine million people in the EU.
December 13, 2024 | 6:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roche's Vabysmo prefilled syringe has received EU approval for treating three retinal conditions, potentially expanding its market reach and benefiting over nine million people.
The approval of Vabysmo in the EU for three retinal conditions is a significant regulatory milestone for Roche, potentially increasing its market share and revenue in the region. The conditions affect a large population, indicating a substantial market opportunity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90